NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
November 20, 2025 — Oncotelic Therapeutics' joint venture pipeline valued at $1.7B, with company's 45% stake estimated at $765M. OT-101 advancing to Phase 3 PDAC trials and Phase 2 combinations.
November 20, 2025 — Oncotelic Therapeutics leads biotech valuation shift with fair-value remeasurements of GMP Bio stake. Learn how GAAP accounting reveals true innovation worth in late-stage pipelines.
November 20, 2025 — Senator Bernie Sanders proposes six healthcare reforms to strengthen the Affordable Care Act in a letter to Congressional Democrats, highlighting ongoing efforts to address the US healthcare crisis.
November 20, 2025 — Trifecta Med Spa clarifies no partnership with Eli Lilly or LillyDirect, confirming independent weight-loss services free from pharmaceutical influence on treatment decisions.
November 20, 2025 — Creative Biolabs expands lipid nanoparticle solutions for mRNA vaccines & gene editing. New LNP products, preparation kits & custom services accelerate next-gen therapy development worldwide.
November 20, 2025 — New special issue examines global progress toward eliminating cervical cancer by 2030. Features innovations in vaccination, screening, and treatment to advance women's health equity worldwide.
November 19, 2025 — NWSL partners with American Heart Association to train all 16 teams in Hands-Only CPR, making it the first US pro sports league with comprehensive cardiac emergency training.
November 19, 2025 — HeartBeam's cable-free ECG technology transforms atrial fibrillation detection with portable 12-lead monitoring. Clinical-grade cardiac diagnostics now accessible anywhere for better heart health management.
November 19, 2025 — Free virtual car seat checks connect parents with safety experts. National Safety Council & Buckle Up for Life program addresses incorrect installation risks for child safety.
November 19, 2025 — Soligenix completes enrollment for Phase 3 FLASH2 study of HyBryte in cutaneous T-cell lymphoma, reporting 48% response rate exceeding expectations. Interim analysis scheduled for 2026.
November 19, 2025 — Soligenix completes enrollment for Phase 3 CTCL study with HyBryte showing 48% response rate. Interim analysis scheduled for 2026 in this rare skin cancer treatment trial.
November 19, 2025 — University of Illinois researchers discover FGD3 protein biomarker that predicts breast cancer patients' response to chemotherapy and immunotherapy treatments, advancing precision medicine.
November 19, 2025 — NeuroOne Medical Technologies announces participation in AES 2025 Annual Meeting and CNS Drug Delivery Summit to showcase innovative neurological disorder treatments.
November 19, 2025 — Hydromer partners with Avem Market Solutions to expand access to advanced medical coating technologies across Europe and UK. Enhanced support for Medtech device developers.
November 19, 2025 — Leonhardt Ventures unveils E-Stent™, the first wireless bioelectric stent for regenerative medicine. Technology controls protein expressions across 29 medical applications from heart to brain health.
November 19, 2025 — SunKnowledge achieves 98% clean claim rate in dental billing, setting new industry standard for revenue cycle management. Faster reimbursements, reduced denials for dental practices nationwide.
November 19, 2025 — VNANNJ launches hospice awareness campaign to address underutilization. Learn how hospice improves end-of-life care and dispel common myths about this vital service.
November 18, 2025 — M1 Kliniken AG reports 11% EBIT growth and 29.7% Beauty segment surge in 2025 results. The medical aesthetics leader targets global expansion with sustainable 20% margins by 2029.
November 18, 2025 — National Hispanic Health Foundation announces 2025 scholarship galas honoring Hispanic health students. Events in LA & DC celebrate future leaders addressing healthcare disparities.
November 18, 2025 — Annovis Bio announces FDA Type C meeting in 2026 for buntanetap in Parkinson's dementia. Company reports continued progress in Phase 3 Alzheimer's trial with full regulatory alignment.